

several novel somatic (e.g., tumor-specific) alterations, many of which have not previously been known to be genetically altered in tumors or linked to melanoma. In particular, the researchers identified a recurrent “hotspot” mutation in the transformation/transcription domain-associated protein (TRRAP) gene, identified the glutamate receptor ionotropic N-methyl D-aspartate 2A (GRIN2A) gene as a highly mutated in melanoma, and have shown that the majority of melanoma tumors have alternations in genes encoding members of the glutamate signaling pathway, such as phospholipase C, beta 4 (PLCB4). Therefore, this technology not only provides a comprehensive map of genetic alterations in melanoma, but has important diagnostic and therapeutic applications.

Available for licensing are several melanoma cell lines that harbor TRRAP, GRIN2A, and PLCB4 mutations. These cell lines provide useful and efficient tools for studying melanoma and can be used in the development of specific therapeutics for patients harboring these mutations. Specifically, these cell lines could be used to develop inhibitors to limit tumor growth and further understand melanoma and the biology of these genes.

Potential Commercial Applications:

- Diagnostic array for the detection of TRRAP, GRIN2A, and PLCB4 mutations.
- Method of identifying TRRAP, GRIN2A, and PLCB4 inhibitors as therapeutic agents to treat malignant melanoma patients.
- In vitro and in vivo cell model for understanding the biology of TRRAP, GRIN2A, and PLCB4, including growth, motility, invasion, and metabolite production.

Competitive Advantages:

- Cell lines are derived from melanoma patients.
- TRRAP, GRIN2A, and PLCB4 mutations are highly frequent and/or highly mutated in melanomas.
- Glutamate antagonists have already been shown to inhibit tumor growth. Thus, this technology may prove useful for the development of novel diagnostic tests and therapeutics.

Development Stage: Pre-clinical

Inventors: Yardena Samuels (NHGRI) and Steven Rosenberg (NCI)

Publication: Wei X, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. *Nat Genet.* 2011 May; 43(5):442–6. [PMID 21499247]

Intellectual Property: HHS Reference No. E–024–2012/0—Research Tool. Patent protection is not being pursued

for the TRRAP, GRIN2A, PLCB4 melanoma metastatic cell lines.

Related Technologies: HHS Reference Nos.—E–013–2011/0 (patent apps. PCT); E–272–2008/0 (patent apps. US, EP); E–229–2010/0 (research tool); E–232–2010/0 (research tool); E–029–2012/0 (research tool); E–244–2012/0 (patent app: PCT)

Licensing Contact: Whitney Hastings; 301–451–7337; hastingw@mail.nih.gov

Collaborative Research Opportunity: The NHGRI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Claire Driscoll, Director, NHGRI Technology Transfer Office, at cdriscoll@mail.nih.gov or 301–594–2235.

Dated: January 31, 2013.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013–02516 Filed 2–5–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Arthritis and Musculoskeletal and Skin Diseases Initial Review Group; Arthritis and Musculoskeletal and Skin Diseases Clinical Trials Review Committee.

Date: March 12–13, 2013.

Time: 8:00 a.m. to 4:00 PM.

Agenda: To review and evaluate grant applications.

Place: Marriott Courtyard Gaithersburg Washingtonian Ctr, 204 Boardwalk Place, Gaithersburg, MD 20878.

Contact Person: Charles H Washabaugh, Ph.D., Scientific Review Officer, National

Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, 6701 Democracy Boulevard, Suite 800, Bethesda, MD 20892, (301) 496–9568, washabac@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: January 30, 2013.

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–02517 Filed 2–5–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Clinical Trial Cobre.

Date: February 27, 2013.

Time: 8:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriott Courtyard Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Lisa A. Newman, SCD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3As.19K, Bethesda, MD 20892–4874, 301–594–2704, newmanla2@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: January 31, 2013.
Melanie J. Gray,
*Program Analyst, Office of Federal Advisory
 Committee Policy.*
 [FR Doc. 2013-02515 Filed 2-5-13; 8:45 am]
BILLING CODE 4140-01-P

**DEPARTMENT OF HOMELAND
 SECURITY**

U.S. Customs and Border Protection

**Relocation of Regulations and Rulings,
 Office of International Trade**

AGENCY: U.S. Customs and Border
 Protection, Department of Homeland
 Security.
ACTION: Notice of change in office
 location.

SUMMARY: Regulations and Rulings, in
 the Office of International Trade, of the
 U.S. Customs and Border Protection
 (CBP) is relocating its office from the
 U.S. Mint Annex Building at 799 9th
 Street NW., Washington, DC to 90 K
 Street NE., Washington, DC 20229-
 1177. All correspondence directed to
 the Regulations and Rulings, Office of
 International Trade, including mailed
 comments regarding section 1625
 modifications or revocations, should be
 sent to the new address. The main office
 phone number remains the same.

DATES: *Effective Date:* February 6, 2013.
FOR FURTHER INFORMATION CONTACT:
 Joseph W. Clark, Trade and Commercial
 Regulations Branch, Regulations and
 Rulings, Office of International Trade,
 (202) 325-0118.

SUPPLEMENTARY INFORMATION:

Background

Regulations and Rulings, Office of
 International Trade, U.S. Customs and
 Border Protection (CBP) is relocating its
 office from the U.S. Mint Annex
 Building at 799 9th Street NW.,
 Washington, DC to 90 K Street NE.,
 Washington, DC 20229-1177. All
 correspondence, including ruling
 requests and mailed comments
 regarding 19 U.S.C. 1625 modifications
 or revocations (*see* 19 CFR 177.12),
 should be directed to the new address,
 as follows: Regulations and Rulings,
 Office of International Trade, U.S.
 Customs and Border Protection, 90 K St.

NE., (10th Floor), Washington, DC
 20229-1177.
 After February 4, 2013, anyone
 wishing to view the mailed comments
 that were submitted to Regulations and
 Rulings in response to a 1625
 modification or revocation (19 CFR
 177.12) published in the **Federal
 Register** should come to the new office
 location specified in the preceding
 paragraph. It is highly recommended
 that a person first call Mr. Joseph Clark
 at (202) 325-0118 to schedule an
 appointment in advance to view the
 comments. Please note that all office
 phone numbers remain the same. The
 main office phone number is 202-325-
 0100.

Dated: January 31, 2013.
Sandra L. Bell,
*Executive Director, Regulations and Rulings,
 Office of International Trade.*
 [FR Doc. 2013-02546 Filed 2-5-13; 8:45 am]
BILLING CODE 9111-14-P

**DEPARTMENT OF HOUSING AND
 URBAN DEVELOPMENT**

[Docket No. FR-5683-N-12]

**Notice of Submission of Proposed
 Information Collection to OMB HUD
 Lead Hazard Control Grantees
 Regarding Their Use of Healthy Homes
 Supplemental Funding**

AGENCY: Office of the Chief Information
 Officer, HUD.
ACTION: Notice.

SUMMARY: The proposed information
 collection requirement described below
 has been submitted to the Office of
 Management and Budget (OMB) for
 review, as required by the Paperwork
 Reduction Act. The Department is
 soliciting public comments on the
 subject proposal.

Requirements for notification of lead
 based paint hazard in federally-owned
 residential properties and housing
 receiving Federal assistance, as codified
 in 24 CFR part 35.

DATES: *Comments Due Date:* March 8,
 2013.

ADDRESSES: Interested persons are
 invited to submit comments regarding
 this proposal. Comments should refer to
 the proposal by name and/or OMB
 approval Number (2539-New) and

should be sent to: HUD Desk Officer,
 Office of Management and Budget, New
 Executive Office Building, Washington,
 DC 20503; fax: 202-395-5806. Email:
OIRA_Submission@omb.eop.gov fax:
 202-395-5806.

FOR FURTHER INFORMATION CONTACT:
 Colette Pollard., Reports Management
 Officer, QDAM, Department of Housing
 and Urban Development, 451 Seventh
 Street SW., Washington, DC 20410;
 email Colette Pollard at
Colette.Pollard@hud.gov. or telephone
 (202) 402-3400. This is not a toll-free
 number. Copies of available documents
 submitted to OMB may be obtained
 from Ms. Pollard.

SUPPLEMENTARY INFORMATION: This
 notice informs the public that the
 Department of Housing and Urban
 Development has submitted to OMB a
 request for approval of the Information
 collection described below. This notice
 is soliciting comments from members of
 the public and affecting agencies
 concerning the proposed collection of
 information to: (1) Evaluate whether the
 proposed collection of information is
 necessary for the proper performance of
 the functions of the agency, including
 whether the information will have
 practical utility; (2) Evaluate the
 accuracy of the agency's estimate of the
 burden of the proposed collection of
 information; (3) Enhance the quality,
 utility, and clarity of the information to
 be collected; and (4) Minimize the
 burden of the collection of information
 on those who are to respond; including
 through the use of appropriate
 automated collection techniques or
 other forms of information technology,
 e.g., permitting electronic submission of
 responses.

**This Notice Also Lists the Following
 Information**

Title of Proposed: Collection of
 Information from HUD Lead Hazard
 Control Grantees Regarding Their Use of
 Healthy Homes Supplemental Funding.

OMB Approval Number: 2539-New.

Form Numbers: None.

*Description of the need for the
 information and proposed use:*
 Requirements for notification of
 leadbased paint hazard in federally-
 owned residential properties and
 housing receiving Federal assistance, as
 codified in 24 CFR part 35.

	Number of respondents	Annual responses	×	Hours per response	Burden hours
Reporting Burden	80	12		32.75	31,440